HealthCore Impact Study: Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction
In celebration of HealthCore’s 25th Anniversary of Founder’s Day, we’re rolling out a series of articles highlighting some of our most impactful work. These ‘impact studies’ have contributed to the growing evidence base that influences healthcare decision makers and healthcare policy and/or practice. They also showcase HealthCore’s diverse service offerings. Though all our work aims to improve the quality of healthcare, we’re especially proud of this work from research teams across our organization.
Preterm birth (any birth before 37 weeks gestation) is the leading cause of illness and death in newborns. According to the 2020 March of Dimes Report Card, of nearly 4 million babies born annually in the U.S., more than one in 10 is born prematurely.
In 2019, HealthCore uncovered an opportunity to significantly reduce the rate of preterm births and potentially improve millions of lives. Researchers found that a blood test (PreTRM®, Sera Prognostics) used to identify pregnant women who are at higher risk of delivering preterm, combined with clinical interventions, had promise to improve outcomes and lower costs.
HealthCore developed an economic model to evaluate the cost-effectiveness of this risk-screening-and-treat strategy, compared to usual care, for a population of commercially insured pregnant women with no known risk factors for preterm birth.
Researchers looked at outcomes from pregnancy start to 12 months post-delivery in mothers and 30-months from birth in infants. Preterm birth rates and costs were based on real-world cohorts of >40,000 mothers and infants with birth events in 2016, as identified in administrative claims.
Reductions were also seen for neonatal-intensive-care-unit admissions (10%), overall length-of-stay (7%), and the number of newborns with high morbidity burden (23%). Sensitivity analyses confirmed robustness of the model and showed the importance of treatment effectiveness in assessing whether the risk-screening-and-treat strategy would be cost-saving.
This study is one of the first economic evaluations using real-world data to assess the potential value of the PreTRM test for preterm birth risk in a commercially insured US population. More than $850 million could be saved annually assuming full uptake of the risk-screen-and-treat strategy and four million births. Such a combination of better outcomes at lower costs is rare in modern healthcare.
Together with Anthem and Sera Prognostics, HealthCore is currently working on the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study: a pragmatic clinical trial that will provide a blueprint for how the healthcare industry can more effectively identify and manage high-risk pregnancies and reduce preterm birth and its sequela.
Contingent on the results of these studies, Anthem will be making the test available to pregnant members – more than 10 percent of US pregnancies annually – as part of a multi-year contract with Sera.
For more information about our Health Economics and Outcomes Research capabilities, including Project Management, Literature Reviews, Data Management, Large and Complex Database Analytics, Machine Learning, Patient and Provider Outreach, Medical Record Review and Abstraction, and Survey-Based-Research, visit our Health Economics & Outcomes Research page.